• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay Kits
      • Transcreener® 2-5A OAS Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Ligase and Synthetase Assay Kits
      • Methyltransferase Assay Kits
      • Phosphodiesterase Assay Kits
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
    • HTS Assays by Target
      • Adenosine Kinase Assay Kits
      • AMPK Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • cGAS Assay Kits
      • DDX3 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • IRAK4 Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • MAPK8 Assay Kits
      • NSP13 Assay Kits
      • NUDT5 Assay Kits
      • OAS Assay Kits
      • PKR Assay Kits
      • TBK1 Assay Kits
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Innate Immunity
    • ADK Activity Assays
    • AMPK Activity Assays
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD38 Activity Assay Services
    • CD39 Activity Assays
    • DDX3 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • IRAK4 Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • MAPK8 Activity Assays
    • NSP13 Activity Assays
    • OAS1 Activity Assays
    • PKR Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

ABC Transporter ATPase Assay Helps Discover MsbA Inhibitors

by Bellbrook Labs / Tuesday, 16 July 2019 / Published in Emerging Targets, HTS Assays, Success Stories
ABC Transporter ATPase Assay Inhibitor

MsbA Inhibitors Help Fight Against Gram-Negative Bacteria

As pathogens continue to wreak havoc on human health, new therapeutics are needed. HTS compatible assays such as the Transcreener ABC Transporter ATPase Assay help pave the way to establish new treatments.

Gram-negative bacterial pathogens pose grave dangers in clinical and environmental settings alike. They include foodborne disease pathogens such as E. coli 0157:H7, waterborne pathogens such as Vibrio cholera, vector-borne pathogens such as Yersinia pestis, and a disturbingly large number of Gram-negative pathogens that now display resistance to multiple antimicrobial agents.1 

Resistant Gram-negative pathogens include some of the most common causes of healthcare-associated infections (HAIs): E. coli (causing urinary tract infections), Acinetobacter baumanii (causing wound infections), Pseudomonas aeruginosa (responsible for bloodstream infections and pneumonia), and Klebsiella pneumoniae (causing various HAIs including pneumonia, urinary tract infections, and bloodstream infections). Multi-drug resistant (MDR) strains of Neisseria gonorrhoeae have been reported (responsible for the sexually transmitted disease gonorrhea, which is the second most commonly reported infectious disease in the United States).1

An estimate of the prevalence of infections due to MDR gram-negative bacilli indicated profound consequences for patient mortality, hospital length of stay, and increased hospital costs.2 By 2050, it has been estimated that multidrug resistance (in total) will be responsible for 300 million deaths and drain up to $100 trillion from the world’s gross domestic product, and gram-negative bacteria are drivers of this trend.3 A recent study of 891 hospitalized patients at one institution with bloodstream infections caused by Gram-negative bacteria indicated that one-third were infected with MDR strains, and this subgroup of infections primarily accounted for increased mean inpatient costs related to bloodstream infections.4

ABC Transporter ATPase Assay Finds Inhibitors Reducing Hospital Length of Stay

ABC Transporter ATPase Assay helps find new MsbA inhibitors that may reduce hospital length of stay for patients in the future.

The peculiar structure of the outer membrane is a key reason that so many antimicrobial agents are ineffective against Gram-negative bacteria. The double membrane of these microbes is asymmetrical, containing phospholipids in the inner leaflet and a complex glycolipid called LPS in the outer leaflet.  Between them is the aqueous periplasm containing a thin layer of peptidoglycan. The journey of LPS to its final destination at the outer membrane involves being “flipped” across the inner membrane by an ABC transporter protein called MsbA in an ATP-driven transport process.5 As a result, MsbA is critical for virulence, and loss of MsbA function causes rapid membrane disruption and cell death.6

Using an ABC Transporter ATPase Assay to Accelerate Discovery

Reasoning that MsbA is a valuable potential antibacterial target, a group of researchers at Genentech screened a library of approximately 3 million small molecules for specific inhibitors of Escherichia coli MsbA.7 The researchers also used the Transcreener ADP2 FP Kit as an ABC Transporter ATPase Assay to determine the IC50 of MsbA inhibitors. The initial discovery of quinolone compound G592 led to the identification of more potent compounds G247 (IC50 of 5 nM) and G907 (IC50 of 18 nM). The team was able to obtain crystals of MsbA in complex with G907 at 2.9 Å resolution, yielding valuable structural data.7

It turns out that G907 traps MsbA in an inward-facing, LPS-bound conformation by wedging into an evolutionarily conserved transmembrane pocket.7 Additionally, a second mechanism of inhibition by G907 happens due to its effect on critical nucleotide-binding domains (NBDs).7

This dual-mode of MbsA antagonism is tantalizing, suggest the authors, because it indicates a possible path toward novel antimicrobial compounds that are desperately needed in the global fight against multidrug-resistance pathogens. “Considering the architectural conservation of the G907-binding pocket in other ABC transporters, this work should enable the discovery of selective antagonists across the broader ABC transporter superfamily,” they write.7

Discovering and evaluating novel MsbA inhibitors using an ABC transporter ATPase Assay can lead to leads such as G907. This requires robust high-throughput assays that are capable of enabling screens of millions of molecules at high sensitivity. Given the economic toll and loss of life that Gram-negative pathogens cause in the inpatient setting alone, a strong arsenal of new antimicrobials is urgently needed, placing a priority on such research efforts.

-Robyn M. Perrin, PhD

Learn More About the ATPase Assay

References
[1] “Gram-negative Bacteria,” National Institutes of Health – National Institute of Allergy and Infectious Diseases, https://www.niaid.nih.gov/research/gram-negative-bacteria, accessed June 4, 2018.

[2] Giske CG, et al. 2008. Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli. Antimicrob. Agents Chemother. 52:813-821.

[3] The Review on Antimicrobial Resistance. 11 December 2014, posting date. Antimicrobial resistance: tackling a crisis for the future health and wealth of nations. https://amr-review.org/sites/default/files/AMR Accessed June 4, 2018.

[4] Thaden JT, etla. 2017. Increased Costs Associated with Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Bacteria Are Due Primarily to Patients with Hospital-Acquired Infections. Antimicrob Agents Chemother. 61(3): e01709-16.

[5] Sperandeo P, et al. 2017. The lipopolysaccharide transport (Lpt) machinery: A nonconventional transporter for lipopolysaccharide assembly at the outer membrane of Gram-negative bacteria. J Biol Chem. 292:17981-17990.

[6] Doerrler WT, et al. 2001. An Escherichia coli mutant defective in lipid export. J Biol. Chem. 276:11461–11464.

[7] Ho H, et al. 2018. Structural basis for dual-mode inhibition of the ABC transporter MsbA. Nature. 557(7704):196-201. https://www.nature.com/articles/s41586-018-0083-5

Tagged under: ABC Transporter ATPase Assay, ATPase Assay, Transcreener ADP ATPase Assay, Transcreener ADP Kinase Assay

What you can read next

Targeting Host Kinases for Hepatitis C Treatment
DHX36 RNA Helicase Unwinds G4 RNA Structures
Resolving the Many Roles of DHX36
tyrosine kinase inhibitor lung cancer
How a Tyrosine Kinase Inhibitor Is Giving Hope to Lung Cancer Patients

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • PARG in Human Immunity

    Discovering the Emerging Importance of PARG in Immunity

    Poly (ADP-ribose) glycohydrolase (PARG), along ...
  • Helicases Used in Innate Immunity

    Helicases as Powerful Tools in Innate Immunity

    Helicases are among the largest and most highly...
  • Info book on cancer and RAFK1's relation

    RAF1 & Immunity: A Future Model For Cancer Research?

    RAF1, also known as c-Raf, is a member of the R...
  • OAS1 The Cost of Host Defense

    OAS1: The Cost of Host Defense

    OAS1 (Oligoadenylate synthetase 1) is induced b...
  • Scientist Studying DDX41

    DDX41 as a Sensor, Suppressor, and Modulator

    DDX41 [DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 4...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP